HBC Hofseth Biocare

Hofseth Biocare ASA: PROXY RIGHTS AT GENERAL MEETING

Hofseth Biocare ASA: PROXY RIGHTS AT GENERAL MEETING

Ola Holen, chairman of the Board of Hofseth BioCare ASA (the "Company" or "HBC"), has in connection with the upcoming extraordinary general meeting on 11 November 2020, received proxy rights without voting instructions from shareholders representing 43,319,914 shares in the Company, equal to approx. 12.21% of the voting rights.

Mr. Holen owns as of the date hereof a total of 1,465,253 shares, equal to 0.41 per cent of the outstanding shares in HBC. 935,388 shares are owned via his fully owned company, Paso AS, and 529,865 shares are held privately.

After the receipt of the above-mentioned proxies, Mr. Holen represents a total of 44,785,167 shares and votes, equal to 12.62% of the voting rights at the upcoming extraordinary general meeting in HBC on 11 November 2020.

For further information, please contact:

Jon Olav Ødegård, CFO of Hofseth BioCare ASA

Mob:

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian biotech company that develops high-value ingredients and finished products. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food to help treat age-related Sarcopenia, and future phase 1 studies on treatment of Anemia and NEC-IBD with Salmon Protein Hydrolysate fractions.

The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts. Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Palo Alto and Tokyo.

HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at hofsethbiocare.com and facebook.com/hofsethbiocare

This information is subject to the disclosure requirements pursuant to Sections 4-3 and 5-12 of the Norwegian Securities Trading Act

EN
09/11/2020

Underlying

HBCHofseth Biocare

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for H...

Hofseth Biocare ASA: HBC’s ProGo® has won Ingredient of the Year for Healthy Aging at the prestigious Nutraingredients USA awards ceremony in Chicago According to the judges, the winning factors placing ProGo® well ahead of the competition are its unique ability to activate GLP-1 and GIP receptors, coupled with its unrivalled sustainability credentials including Upcycled Certified by WFCF (Where Food Comes From). Most significantly, these benefits are supported and evidenced through two clinical studies demonstrating weight loss with ProGo®. ProGo® Bioactive Peptides optimize the metabolis...

July 16, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: Annual General Meeting completed

Hofseth Biocare ASA: Annual General Meeting completed Hofseth BioCare ASA held its Annual General Meeting on 23 May 2025. All proposals were resolved as presented in the notice issued on 2 May 2025. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: E-mail: About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry by takin...

May 23, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT

Hofseth Biocare ASA: FIRST QUARTER 2025 FINANCIAL REPORT HBC recorded total operating revenues of NOK 60.9 million in the first quarter of 2025, compared to NOK 52.4 million in the same period last year. Net operating revenues were NOK 60.7 million, reflecting a 15% increase from Q1 2024 (NOK 52.1 million), driven by continued growth in higher-margin human and pet health segments, despite early-quarter production constraints and ongoing pressure in the commodity oil market. Cost of goods sold (CoGS) amounted to NOK 37.5 million, up from NOK 27.3 million in Q1 2024. Operating expenses total...

May 16, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SP...

Hofseth Biocare ASA: NESTLÉ GARDEN OF LIFE LAUNCHES HBC OMEGO® FULL SPECTRUM OMEGAS IN THE US Nestlé-owned Garden of Life has launched OmeGo® Full Spectrum Omegas on Amazon in the US. Branded as “Norwegian Salmon Oil”, it retains the complete balance and nutritional profile of fresh Atlantic salmon in a softgel format. Joining Garden of Life’s portfolio of health supplements available online, Norwegian Salmon Oil containing OmeGo® is gently liberated from fresh, sashimi-grade salmon and provides whole-fish health benefits from its full spectrum of omegas. It differentiates from a competiti...

May 5, 2025 1 EN
 PRESS RELEASE
Free
HBC HOFSETH BIOCARE

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSEC...

Hofseth Biocare ASA: SUCCESSFUL PLACEMENT OF NEW CHF-DENOMINATED UNSECURED BONDS Reference is made to the stock exchange notice published by Hofseth BioCare ASA (the "Company") on 10 March 2025 regarding a contemplated bond issuance. The Company is pleased to announce that it has now successfully placed CHF-denominated unsecured bonds for a total amount of approximately CHF 3.5 million (the "Bonds"). The Bonds were subscribed for by investors in Switzerland and Liechtenstein. Settlement of the Bonds issue is expected to occur simultaneously as the issue date, which is expected to be on 5 M...

May 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch